Do analysts rate TIL or BLRX?

Instil Bio presently has a consensus price target of $66.00, indicating a potential upside of 739.16%. Given Instil Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Instil Bio is more favorable than BioLineRx. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TIL or BLRX more profitable?

Instil Bio has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. Instil Bio's return on equity of -26.78% beat BioLineRx's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -26.78% -14.89% BioLineRx -563.70% -37.73% -19.42%

Do analysts prefer BLRX or ATYR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25

Which has stronger valuation and earnings, BLRX or ATYR?

BioLineRx has higher revenue and earnings than aTyr Pharma. BioLineRx is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioLineRx $1.18M 10.39 -$1.17M -$1.92 N/A aTyr Pharma $190K 284.46 -$74.12M -$0.62 N/A

Is BLRX or ATYR more profitable?

aTyr Pharma has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets BioLineRx -563.70% -37.73% -19.42% aTyr Pharma N/A -95.89% -69.67%

Does the media favor BLRX or ATYR?

In the previous week, BioLineRx had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for BioLineRx and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.94 beat BioLineRx's score of 0.87 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLineRx 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BLRX or ALPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ALPS Group Inc Ordinary Share 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BKHA or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, BKHA or BLRX?

Black Hawk Acquisition has higher earnings, but lower revenue than BioLineRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A BioLineRx $1.18M 10.39 -$1.17M -$1.92 N/A

Does the media refer more to BKHA or BLRX?

In the previous week, Black Hawk Acquisition and Black Hawk Acquisition both had 3 articles in the media. Black Hawk Acquisition's average media sentiment score of 1.32 beat BioLineRx's score of 0.87 indicating that Black Hawk Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Hawk Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioLineRx 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BLRX or TCRT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

BioLineRx (BLRX) Competitors

$2.80 +0.11 (+3.89%)

As of 02:44 PM Eastern

Compare

BLRX vs. TIL, ATYR, ALPS, BKHA, and TCRT

Should you buy BioLineRx stock or one of its competitors? BioLineRx's main competitors and comparable companies include Instil Bio (TIL), aTyr Pharma (ATYR), ALPS Group Inc Ordinary Share (ALPS), Black Hawk Acquisition (BKHA), and Alaunos Therapeutics (TCRT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioLineRx compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

BioLineRx has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A
BioLineRx	$1.18M	10.39	-$1.17M	-$1.92	N/A

Instil Bio has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. Instil Bio's return on equity of -26.78% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-26.78%	-14.89%
BioLineRx	-563.70%	-37.73%	-19.42%

Instil Bio has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

In the previous week, BioLineRx had 2 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for BioLineRx and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.43 beat BioLineRx's score of 0.87 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Positive
BioLineRx	Positive

Instil Bio presently has a consensus price target of $66.00, indicating a potential upside of 739.16%. Given Instil Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Instil Bio is more favorable than BioLineRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 1.1% of BioLineRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Instil Bio beats BioLineRx on 9 of the 14 factors compared between the two stocks.

How does BioLineRx compare to aTyr Pharma?

BioLineRx (NASDAQ:BLRX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 5.8% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

BioLineRx has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

aTyr Pharma has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
aTyr Pharma	N/A	-95.89%	-69.67%

In the previous week, BioLineRx had 1 more articles in the media than aTyr Pharma. MarketBeat recorded 3 mentions for BioLineRx and 2 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.94 beat BioLineRx's score of 0.87 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLineRx	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
aTyr Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLineRx has higher revenue and earnings than aTyr Pharma. BioLineRx is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	10.39	-$1.17M	-$1.92	N/A
aTyr Pharma	$190K	284.46	-$74.12M	-$0.62	N/A

Summary

aTyr Pharma beats BioLineRx on 10 of the 16 factors compared between the two stocks.

How does BioLineRx compare to ALPS Group Inc Ordinary Share?

BioLineRx (NASDAQ:BLRX) and ALPS Group Inc Ordinary Share (NASDAQ:ALPS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ALPS Group Inc Ordinary Share	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ALPS Group Inc Ordinary Share has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. ALPS Group Inc Ordinary Share's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
ALPS Group Inc Ordinary Share	N/A	N/A	N/A

In the previous week, BioLineRx had 1 more articles in the media than ALPS Group Inc Ordinary Share. MarketBeat recorded 3 mentions for BioLineRx and 2 mentions for ALPS Group Inc Ordinary Share. BioLineRx's average media sentiment score of 0.87 beat ALPS Group Inc Ordinary Share's score of 0.45 indicating that BioLineRx is being referred to more favorably in the media.

Company	Overall Sentiment
BioLineRx	Positive
ALPS Group Inc Ordinary Share	Neutral

BioLineRx has higher earnings, but lower revenue than ALPS Group Inc Ordinary Share. BioLineRx is trading at a lower price-to-earnings ratio than ALPS Group Inc Ordinary Share, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	10.39	-$1.17M	-$1.92	N/A
ALPS Group Inc Ordinary Share	$4.86M	13.59	-$2.01M	$0.33	1.20

1.6% of BioLineRx shares are held by institutional investors. Comparatively, 27.9% of ALPS Group Inc Ordinary Share shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 25.5% of ALPS Group Inc Ordinary Share shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BioLineRx has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, ALPS Group Inc Ordinary Share has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Summary

ALPS Group Inc Ordinary Share beats BioLineRx on 9 of the 13 factors compared between the two stocks.

How does BioLineRx compare to Black Hawk Acquisition?

Black Hawk Acquisition (NASDAQ:BKHA) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Black Hawk Acquisition has higher earnings, but lower revenue than BioLineRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
BioLineRx	$1.18M	10.39	-$1.17M	-$1.92	N/A

Black Hawk Acquisition has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.54, indicating that its stock price is 54% more volatile than the broader market.

1.6% of BioLineRx shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Black Hawk Acquisition has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. Black Hawk Acquisition's return on equity of 0.00% beat BioLineRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
BioLineRx	-563.70%	-37.73%	-19.42%

In the previous week, Black Hawk Acquisition and Black Hawk Acquisition both had 3 articles in the media. Black Hawk Acquisition's average media sentiment score of 1.32 beat BioLineRx's score of 0.87 indicating that Black Hawk Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Hawk Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLineRx	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Black Hawk Acquisition and BioLineRx tied by winning 4 of the 8 factors compared between the two stocks.

How does BioLineRx compare to Alaunos Therapeutics?

BioLineRx (NASDAQ:BLRX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

BioLineRx has a beta of 1.54, suggesting that its share price is 54% more volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1, suggesting that its share price is 200% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BioLineRx had 2 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 3 mentions for BioLineRx and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat BioLineRx's score of 0.87 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
BioLineRx	Positive
Alaunos Therapeutics	Very Positive

BioLineRx has higher revenue and earnings than Alaunos Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLineRx	$1.18M	10.39	-$1.17M	-$1.92	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$1.91	N/A

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alaunos Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -563.70%. BioLineRx's return on equity of -37.73% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLineRx	-563.70%	-37.73%	-19.42%
Alaunos Therapeutics	N/A	-232.60%	-158.99%

Summary

BioLineRx and Alaunos Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get BioLineRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLRX vs. The Competition

Export

Metric	BioLineRx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.26M	$4.01B	$7.23B	$12.91B
Dividend Yield	N/A	3.63%	2.54%	11.02%
P/E Ratio	-1.46	11.38	271.89	24.27
Price / Sales	10.39	1,315.35	609.79	79.60
Price / Cash	N/A	108.37	79.89	53.65
Price / Book	0.52	16.66	13.09	6.26
Net Income	-$1.17M	-$22.76M	$3.46B	$347.96M
7 Day Performance	1.63%	3.54%	2.03%	1.47%
1 Month Performance	-0.53%	11.86%	8.23%	4.69%
1 Year Performance	-23.78%	58.52%	26.31%	16.97%

BioLineRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLRX BioLineRx	0.5354 of 5 stars	$2.81 +3.9%	N/A	-25.2%	$12.26M	$1.18M	N/A	40	Upcoming Earnings
TIL Instil Bio	2.7712 of 5 stars	$7.31 -0.7%	$66.00 +802.9%	-72.4%	$49.56M	N/A	N/A	410	News Coverage Positive News
ATYR aTyr Pharma	1.0967 of 5 stars	$0.50 -2.9%	$17.00 +3,272.3%	-89.3%	$49.45M	$190K	N/A	53
ALPS ALPS Group Inc Ordinary Share	1.0071 of 5 stars	$0.30 -7.7%	N/A	N/A	$49.19M	$4.86M	0.90	N/A	Short Interest Increase Gap Down
BKHA Black Hawk Acquisition	N/A	$11.80 -0.3%	N/A	+8.0%	$49.02M	N/A	N/A	N/A	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLRX) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioLineRx (BLRX) Competitors

BLRX vs. TIL, ATYR, ALPS, BKHA, and TCRT

How does BioLineRx compare to Instil Bio?

Summary

How does BioLineRx compare to aTyr Pharma?

Summary

How does BioLineRx compare to ALPS Group Inc Ordinary Share?

Summary

How does BioLineRx compare to Black Hawk Acquisition?

Summary

How does BioLineRx compare to Alaunos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioLineRx (BLRX) Competitors

BLRX vs. TIL, ATYR, ALPS, BKHA, and TCRT

How does BioLineRx compare to Instil Bio?

Which has higher valuation & earnings, TIL or BLRX?

Is TIL or BLRX more profitable?

Which has more risk & volatility, TIL or BLRX?

Does the media prefer TIL or BLRX?

Do analysts rate TIL or BLRX?

Do insiders & institutionals believe in TIL or BLRX?

Summary

How does BioLineRx compare to aTyr Pharma?

Do insiders and institutionals hold more shares of BLRX or ATYR?

Which has more risk & volatility, BLRX or ATYR?

Do analysts prefer BLRX or ATYR?

Is BLRX or ATYR more profitable?

Does the media favor BLRX or ATYR?

Which has stronger valuation and earnings, BLRX or ATYR?

Summary

How does BioLineRx compare to ALPS Group Inc Ordinary Share?

Do analysts prefer BLRX or ALPS?

Is BLRX or ALPS more profitable?

Does the media favor BLRX or ALPS?

Which has higher valuation and earnings, BLRX or ALPS?

Do institutionals and insiders believe in BLRX or ALPS?

Which has more risk and volatility, BLRX or ALPS?

Summary

How does BioLineRx compare to Black Hawk Acquisition?

Do analysts prefer BKHA or BLRX?

Which has preferable earnings & valuation, BKHA or BLRX?

Which has more volatility and risk, BKHA or BLRX?

Do insiders and institutionals have more ownership in BKHA or BLRX?

Is BKHA or BLRX more profitable?

Does the media refer more to BKHA or BLRX?

Summary

How does BioLineRx compare to Alaunos Therapeutics?

Which has more risk and volatility, BLRX or TCRT?

Do analysts rate BLRX or TCRT?

Does the media prefer BLRX or TCRT?

Which has stronger earnings and valuation, BLRX or TCRT?

Do insiders and institutionals have more ownership in BLRX or TCRT?

Is BLRX or TCRT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLRX vs. The Competition

BioLineRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools